{
    "nct_id": "NCT03248531",
    "official_title": "A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa",
    "inclusion_criteria": "* Adult subjects (18 to 70 years of age, inclusive) must have a diagnosis of HS for at least\n\n  1 year prior to Baseline\n* Stable HS for at least 2 months prior to Screening and also at the Baseline Visit\n* Inadequate response to at least a 3-month study of an oral antibiotic for treatment of HS\n* Total abscess and inflammatory nodule count >=3 at the Baseline Visit\n* Subject must agree to daily use (and throughout the entirety of the study) of 1 pre-specified over-the-counter topical antiseptics on their HS lesions\n* Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug and have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose\n* Male subjects must be willing to use a method of contraception when sexually active, up till 20 weeks after the last administration of study medication\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Prior treatment with anti-IL17s or participation in an anti-IL17 study\n* Previously received anti-TNFs\n* Subject requires, or is expected to require, opioid analgesics for any reason (excluding tramadol)\n* Subject received prescription topical therapies for the treatment of HS within 14 days prior to the Baseline Visit\n* Subject received systemic non-biologic therapies for HS with potential therapeutic impact for HS less than 28 days prior to Baseline Visit\n* Draining fistula count >20 at the Baseline Visit\n* Diagnosis of inflammatory conditions other than HS",
    "miscellaneous_criteria": ""
}